The Science Behind Mindstrong

Mindstrong’s science begins with the smartphone. With over three billion smartphones globally and more than 75% of American adults owning a smartphone (92% between ages 18 – 29), this powerful mobile computer has become ubiquitous. Digital phenotyping collects data from the smartphone to provide measures of emotion, cognition, and behavior. In three rigorous clinical studies with over 200 person-years of data, Mindstrong has used powerful machine learning analytics to show that specific digital features correlate with cognitive function, clinical symptoms, and measures of brain activity.

Science_Illustration_v3@2x
th_Science_visual_2

Digital phenotyping uses three kinds of signals from a smartphone. Sensors measure activity, location, and social meta-data (e.g. number of messages out vs messages in). Human-computer interactions capture keyboard performance including typing and clicking. Voice and speech data analyzed with natural language processing can yield insights into emotion and cognitive coherence. Together these signals contribute to the picture of mood, cognition, and behavior we call the digital phenotype.

Individual Biomarkers Load on Distinct Cognitive Domains
Science_Chart_1

To identify the digital phenotyping features that could be clinically useful, research volunteers completed extensive neuropsychological testing, clinical assessments of mood and cognition, and, in some cases, neuroimaging with fMRI. The results revealed a set of digital biomarkers from human-computer interaction (keyboard performance) that correlate highly with select cognitive measures and brain connectivity.

Individual Biomarkers Load on Distinct Neural Circuits
science chart 3 v3.2
Science_Chart_2_v2@1x

In those research subjects with depression who volunteered for fMRI brain scans (n = 100), specific digital biomarkers from human-computer interaction that correlated with neuropsychological measures of cognitive control and reward also correlated highly with activity in those brain areas implicated in cognitive control and reward.

While single markers correlated highly with cognitive and neural features, combining markers yielded even higher correlations. In one study with 100 patients with depression, combining biomarkers yielded high correlations with the PHQ-9, a gold standard measure of depression.

Biomarker Loading on Depression Constructs
Science_Chart_3_notitle

  Mindstrong biomarker platform was used by the National Institutes of Health grant UH2HL132368 “Engaging self-regulation targets to understand the mechanisms of behavior change and improve mood and weight outcomes”.

These initial studies demonstrate the feasibility of using digital phenotyping to collect data over a full year in research volunteers. Will this approach improve outcomes in clinical practice? Our current studies address this question for people with serious mental illness. Mindstrong’s scientific challenge is to go beyond predicting current measures to develop novel objective measures that can predict relevant outcomes and yield precise diagnostic information – the scientific basis of predictive medicine and precision medicine.

Clinical Trials

Mindstrong Health is participating in several trials selected to test the value of digital phenotyping in clinical populations.

Intellectual Property

Mindstrong has developed and patented a biomarker panel that measures brain function from interaction patterns captured passively and continuously from human-computer interfaces found in ubiquitous mobile technology.

 

Digital biomarkers of cognitive function

Paul Dagum

This publication describes the study used to identify digital biomarkers that predict performance on gold standard neurocognitive tests.

Related Content: Behind the Paper. This accompanying article describes the story behind Mindstrong’s technology, and the journey Paul Dagum, Founder and CEO, took to develop the pioneering concept and work.

Assessing Anhedonia with Quantitative Tasks, Digital and Patient Reported Measures in a Multi-Center, Double-Blind Trial With BTRX-246040 for the Treatment of Major Depressive Disorder

Annette Madrid, Daniel Smith, Sarah Alvarez-Horine, Kerensa Saljooqi, Paul Dagum, Atul Mahableshwarkar

This poster reports preliminary results from a Phase 2A trial of BTRX-246040, a potent and selective antagonist of the human nociception receptor (NOPR), as a treatment for anhedonia in patients with major depressive disorder. Mindstrong’s digital phenotyping is one of the outcome measures being used to assess efficacy.

Join the Disruptors of Health Science

Thomas R. Insel

This Commentary describes the changing ecosystem as small and large tech companies become involved in biomedical research and healthcare.

Digital Phenotyping: Technology for a New Science of Behavior

Thomas R. Insel

This JAMA Viewpoint article describes digital phenotyping as a new technology for providing passive, objective, continuous information for diagnosing and monitoring mental illness.